ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
3.450
-0.020 (-0.58%)
Jan 31, 2025, 9:34 AM EST - Market open
ImmunityBio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ImmunityBio stock have an average target of 13.58, with a low estimate of 4.75 and a high estimate of 30. The average target predicts an increase of 293.62% from the current stock price of 3.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +769.57% | Jan 30, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +769.57% | Jan 27, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +769.57% | Jan 16, 2025 |
| BTIG | BTIG | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +73.91% | Jan 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +769.57% | Jan 6, 2025 |
Financial Forecast
Revenue This Year
15.30M
from 622.00K
Increased by 2,359.81%
Revenue Next Year
138.94M
from 15.30M
Increased by 808.10%
EPS This Year
-0.85
from -1.15
EPS Next Year
-0.69
from -0.85
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 17.1M | 179.3M | 284.0M | |||
| Avg | 15.3M | 138.9M | 234.2M | |||
| Low | 12.8M | 107.2M | 185.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2,651.6% | 1,071.9% | 104.4% | |||
| Avg | 2,359.8% | 808.1% | 68.6% | |||
| Low | 1,964.0% | 600.7% | 33.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.70 | -0.44 | -0.28 | |||
| Avg | -0.85 | -0.69 | -0.45 | |||
| Low | -1.13 | -1.00 | -0.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.